Search clinical trials for: long-acting beta2-agonist

Total 16473 results

Far Eastern Memorial Hospital

Withdrawn

Impact of Beta-3 Agonist on Psychological Distress and Blood Flow of the Bladder in Women With Overactive Bladder Syndrome

Overactive Bladder Syndrome

Taiwan
GlaxoSmithKline

Completed

Regulatory Nebilet PMS (Nebilet PMS)

Heart Failure | Hypertension

Korea, Republic of
Seoul National University Hospital

Unknown

MIrabegron With oveRACtive bLadder Symptoms in mEn

Overactive Bladder

Korea, Republic of
AstraZeneca

Completed

Multiple Ascending Doses (MAD) of AZD3199 Given Once Daily as Inhaled Formulation Via Turbuhaler to Healthy Men (AZD3199MAD)

Healthy Volunteers

Sweden
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)

Overactive Bladder

Poland, United Kingdom, Germany, Spain, Netherlands, Belgium, Czech Republic, Italy, Norway, Hungary, Sweden, Denmark, Greece, France, Russian Federation
Astellas Pharma Inc

Completed

Study of the Effect of Food on the Pharmacokinetics of Mirabegron

Healthy | Pharmacokinetics of Mirabegron

United States
Mylan Bertek Pharmaceuticals

Completed

A Study of the Safety and Efficacy of Nebivolol in Hypertensive Patients

Hypertension

United States
GlaxoSmithKline

Withdrawn

Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study (LEGEND)

Pulmonary Disease, Chronic Obstructive

United States
University of Kentucky
Kentucky Lung Cancer Research Program

Completed

Optimization of Smoking Cessation Strategies Concurrent With Treatment of Tobacco Related Malignancies

Head and Neck Cancer | Lung Cancer

United States
Rush University Medical Center
National Heart, Lung, and Blood Institute (NHLBI); GlaxoSmithKline

Completed

Using Mobile Phones to Improve Adherence to Inhaled Steroids (ADEPT4)

Asthma

United States
Novo Nordisk A/S

Completed

Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B

Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

Spain
Boehringer Ingelheim

Completed

Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data

Pulmonary Disease, Chronic Obstructive

China
UMC Utrecht
KU Leuven; Maastricht University Medical Center; Universiteit Antwerpen; Université...

Withdrawn

Bronchodilators for Wheeze in Young Children Presenting to Primary Care: a Randomised, Placebo-controlled, Multicentre, Parallel Group Trial (KIWI)

Wheezing
Theodore R. Brown, MD MPH
Astellas Pharma Inc

Completed

Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis (MIRROR)

Multiple Sclerosis

United States
Baylor College of Medicine

Completed

Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain

Ureteral Obstruction | Flank Pain

United States
Assistance Publique - Hôpitaux de Paris
Association Française contre les Myopathies (AFM), Paris

Completed

Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy (NEBIDYS)

Heart Failure | Duchenne Muscular Dystrophy | Cardiomyopathy

France
University of California, San Diego
Forest Laboratories

Completed

Effects of the Beta-blocker Nebivolol (Bystolic) on Subjects With High Normal Blood Pressure and/or a Family History of Hypertension

Hypertension | Pre-hypertension

United States
Buddhist Tzu Chi General Hospital

Completed

Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan

Urinary Incontinence | Overactive Bladder Syndrome
Astellas Pharma Inc
Astellas Pharma Taiwan, Inc.

Completed

A Study to Investigate the Safety and Effect of Food on the Pharmacokinetics of YM178 in Healthy Volunteers

Healthy Volunteer | Pharmacokinetics of YM178

Taiwan
Astellas Pharma Inc

Completed

A Study to Evaluate Absorption, Distribution and Elimination of Mirabegron After Oral Administration to Non-elderly Healthy Chinese Subjects

Healthy Subjects | Plasma Concentration of Mirabegron

Japan
Astellas Pharma Inc

Completed

Specified Drug Use-results Survey of Betanis Tablets

Overactive Bladder

Japan
Otto Muzik

Unknown

Efficacy of Pharmacological Stimulation of BAT and WAT in Lean and Obese Young Adults (MiraBAT)

Brown Fat

United States
Astellas Pharma Inc

Completed

A Study to Investigate the Food Effect on the Pharmacokinetics of YM178 in Healthy, Non-elderly Volunteers

Healthy Volunteer | Pharmacokinetics of YM178

Japan
AstraZeneca

Completed

Evaluation of the Pharmacokinetics and the Pharmacodynamics of Different Dry Powder Inhalation Formulations of AZD3199 in Patients With Asthma

Asthma

Sweden
Jagiellonian University
University Hospital in Krakow

Not yet recruiting

Beta-blockade in Unruptured Intracranial Aneurysm (BBLURAN)

Intracranial Aneurysm

Poland
Philip Kern
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Mechanisms for Activation of Beige Adipose Tissue in Humans

PreDiabetes

United States
Astellas Pharma China, Inc.

Completed

A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder

Urge Incontinence | Overactive Bladder (OAB)

China
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder

Overactive Bladder | Pharmacokinetics of Mirabegron | Neurogenic Detrusor Overactivity

Belgium, Denmark, Norway, Poland, Serbia
Astellas Pharma Global Development, Inc.

Completed

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB) (PILLAR)

Overactive Bladder (OAB)

United States, Canada
Philadelphia Urosurgical Associates
Astellas Pharma Global Development, Inc.

Terminated

A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis (MirabegronIC)

Cystitis, Interstitial

United States
Astellas Pharma Inc

Completed

A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (ARIES)

Urinary Bladder, Overactive

United States, Canada
Astellas Pharma Inc

Completed

A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (CAPRICORN)

Urinary Bladder, Overactive

United States, Hungary, Canada, Spain, Finland, Slovakia, Czechia, Sweden, Germany, Denmark, Norway
Massachusetts General Hospital
Forest Laboratories

Completed

Study to Evaluate Effect of Nebivolol on Angina in Women With Microvascular Disease (NIRVANA)

Microvascular Angina

United States
Astellas Pharma Inc

Completed

A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)

Lower Urinary Tract Symptoms | Bladder Outlet Obstruction

United States, Canada
Astellas Pharma Inc

Completed

A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment

Renal Impairment

United States
Marcus Saemann

Completed

Treat-to-target Trial of Basal Insulin in Post-transplant Hyperglycemia (TIP)

Hyperglycemia

Austria
University of California, San Diego

Recruiting

ADRB3 Signaling Pathway in Human Adipose Tissue

Obesity, Prediabetes

United States
Ain Shams University

Recruiting

Evaluating the Outcome of Cardio Selective beta1- Blockers Use in Patients With Copd

Copd

Egypt
National Taiwan University Hospital

Completed

Predictors for Retreatement of OAB After DC Mirabegron

Recurrence of Overactive Bladder Syndrome

Taiwan
Astellas Pharma Inc

Completed

Long-Term Specified Drug Use-results Survey of Betanis Tablets

Overactive Bladder

Japan
Women and Infants Hospital of Rhode Island
Patient-Centered Outcomes Research Institute; University of California, San... and other collaborators

Recruiting

Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence (BEST)

Urgency Urinary Incontinence

United States
Giulio Stefanini
Agenzia Italiana del Farmaco

Active, not recruiting

Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines (CONTROL)

Lymphoma, Large B-Cell, Diffuse | Breast Cancer | Chemotherapy Effect | Cardiotoxicity | Left Ventricular Dysfunction

Italy
Forest Laboratories

Completed

Nebivolol in Patients With Systolic Stage 2 Hypertension (NEB-MD-20)

Hypertension

United States
Daniel Burdick, MD
Astellas Pharma US, Inc.

Completed

A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO) (Maestro)

Parkinsons Disease

United States
HealthPartners Institute

Completed

Mirabegron in Parkinson Disease and Impaired Cognition (MICT-PD)

Overactive Bladder | Parkinson Disease | Impaired Cognition

United States
Astellas Pharma Inc

Completed

Pharmacokinetics of Oral Mirabegron With Different Release Rates Versus Intravenous (IV) Mirabegron

Healthy | Pharmacokinetics of Mirabegron

United States
Icahn School of Medicine at Mount Sinai
Forest Laboratories

Completed

Effect of Nebivolol on the Blood Flow in Hearts of Adults With High Blood Pressure and Abnormal Filling of Heart

Hypertension | Left Ventricular Diastolic Dysfunction

United States
ZetrOZ, Inc.

Completed

Sustained Acoustic Medicine Ultrasound Diathermy Clinical Performance

Measurement of Diathermy on Anatomical Locations of the Body

United States
University of Tennessee Graduate School of Medicine
Mylan Pharmaceuticals Inc

Recruiting

Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD

COPD Exacerbation

United States
Universitaire Ziekenhuizen KU Leuven

Terminated

Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 3 (BioSput-Air)

Asthmatic Patients

Belgium

Search clinical trials for: long-acting beta2-agonist

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations